Skip to main content
. Author manuscript; available in PMC: 2009 Oct 9.
Published in final edited form as: Nature. 2009 Mar 11;458(7239):725–731. doi: 10.1038/nature07782

Figure 3. PIK3CA activating mutations or PTEN loss suppress tumour sensitivity to DR.

Figure 3

a, Phospho-S473 Akt and total Akt levels in DLD-WT and DLD-Mut cells in the presence or absence of serum for 1 or 24 hours. b, c, and f, Proliferation curves of DLD-WT, DLD-Mut, and doxycycline(Dox)-treated (1µg/ml) U87-MG cells in the presence of increasing concentrations of insulin or IGF-1, n=6. * indicates P ≤ 0.001 as in Fig. 2a, b. d, Volumes of DLD-WT and DLD-Mut tumours in AL or DR mice (n= 7–10). e, PTEN, phospho-S473 Akt and total Akt levels in U87-MG cells in the presence or absence of Dox (left panel) and in Dox-treated U87-MG cells in the presence or absence of serum for 1 hour or 24 hours (right panel). g, Volumes of U87-MG tumours in AL and DR mice administered drinking water with or without Dox (n= 7–9). Data in b, c, d, f and g represent means ± s.e.m.